Literature DB >> 15777692

RNA interference of PPARgamma using fiber-modified adenovirus vector efficiently suppresses preadipocyte-to-adipocyte differentiation in 3T3-L1 cells.

Tetsuji Hosono1, Hiroyuki Mizuguchi, Kazufumi Katayama, Naoya Koizumi, Kenji Kawabata, Teruhide Yamaguchi, Shinsaku Nakagawa, Yoshiteru Watanabe, Tadanori Mayumi, Takao Hayakawa.   

Abstract

The peroxisome proliferator-activated receptor (PPAR) gamma is regarded as a "master regulator" of adipocyte differentiation and is abundantly expressed in adipose. To understand the biological role of PPARgamma in adipose, RNA interference (RNAi) of PPARgamma should be a powerful tool. 3T3-L1 cell line serves an excellent model to investigate the mechanism of preadipocyte-to-adipocyte differentiation. However, this cell line is difficult to transfect by plasmid vectors and viral vectors. We optimized the transduction of both 3T3-L1 preadipocytes and adipocytes by means of fiber-modified adenovirus (Ad) vectors. Among the various vectors tested, polylysine modification of the C-terminal of the fiber knob most markedly improved the transduction efficiency in both 3T3-L1 preadipocytes and adipocytes. Then, we examined whether fiber-modified Ad vectors with polylysine peptides expressing the small interfering RNA (siRNA) for PPARgamma inhibit the differentiation of 3T3-L1 preadipocytes into adipocytes. Oil red O staining and measurement of glycerol-3-phosphate dehydrogenase (GPDH) activity indicated that the vectors effectively suppressed the differentiation of 3T3-L1 preadipocytes to adipocytes. These results suggested that the combination of fiber-modified Ad vectors containing polylysine peptides and RNAi is an effective tool for the study of the biological and physiological mechanism of adipogenesis in adiposity and diabetes using 3T3-L1 models. Ad vector-mediated RNAi for PPARgamma should also be useful to clarify the biological role of the PPARgamma pathway in various tissues in addition to adipose and for therapeutic application to a variety of diseases, including adiposity and diabetes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15777692     DOI: 10.1016/j.gene.2005.01.005

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  11 in total

Review 1.  Minireview: PPARγ as the target of obesogens.

Authors:  Amanda Janesick; Bruce Blumberg
Journal:  J Steroid Biochem Mol Biol       Date:  2011-01-18       Impact factor: 4.292

2.  Heme induced oxidative stress attenuates sirtuin1 and enhances adipogenesis in mesenchymal stem cells and mouse pre-adipocytes.

Authors:  Nitin Puri; Komal Sodhi; Michael Haarstad; Dong Hyun Kim; Steven Bohinc; Eleonora Foglio; Gaia Favero; Nader G Abraham
Journal:  J Cell Biochem       Date:  2012-06       Impact factor: 4.429

3.  Use of small interfering ribonucleic acids to inhibit the adipogenic effect of alcohol on human bone marrow-derived mesenchymal cells.

Authors:  Qiang Huang; Hui Zhang; Fu-xing Pei; Zhi-yu Chen; Guang-lin Wang; Bin Shen; Jing Yang; Zong-ke Zhou; Qing-quan Kong
Journal:  Int Orthop       Date:  2009-12-05       Impact factor: 3.075

4.  7-Chloroarctinone-b as a new selective PPARgamma antagonist potently blocks adipocyte differentiation.

Authors:  Yong-tao Li; Li Li; Jing Chen; Tian-cen Hu; Jin Huang; Yue-wei Guo; Hua-liang Jiang; Xu Shen
Journal:  Acta Pharmacol Sin       Date:  2009-08-17       Impact factor: 6.150

5.  Developmentally spliced PKCbetaII provides a possible link between mTORC2 and Akt kinase to regulate 3T3-L1 adipocyte insulin-stimulated glucose transport.

Authors:  E Kleiman; G Carter; T Ghansah; N A Patel; D R Cooper
Journal:  Biochem Biophys Res Commun       Date:  2009-08-15       Impact factor: 3.575

6.  A novel semisynthetic molecule icaritin stimulates osteogenic differentiation and inhibits adipogenesis of mesenchymal stem cells.

Authors:  Hui Sheng; Xue-fei Rui; Chun-Jun Sheng; Wen-Jun Li; Xiao-Yun Cheng; Navina Priya Jhummon; Yong-Chun Yu; Shen Qu; Ge Zhang; Ling Qin
Journal:  Int J Med Sci       Date:  2013-04-23       Impact factor: 3.738

7.  Rosiglitazone but not losartan prevents Nrf-2 dependent CD36 gene expression up-regulation in an in vivo atherosclerosis model.

Authors:  Y Hernandez-Trujillo; F Rodriguez-Esparragon; A Macias-Reyes; A Caballero-Hidalgo; Jose C Rodriguez-Perez
Journal:  Cardiovasc Diabetol       Date:  2008-02-26       Impact factor: 9.951

8.  Neuroprotective Properties of a Novel Non-Thiazoledinedione Partial PPAR- γ Agonist against MPTP.

Authors:  Christine R Swanson; Eric Du; Delinda A Johnson; Jeffrey A Johnson; Marina E Emborg
Journal:  PPAR Res       Date:  2013-10-02       Impact factor: 4.964

9.  A novel role for adipose ephrin-B1 in inflammatory response.

Authors:  Takuya Mori; Norikazu Maeda; Kana Inoue; Ryohei Sekimoto; Yu Tsushima; Keisuke Matsuda; Masaya Yamaoka; Takayoshi Suganami; Hitoshi Nishizawa; Yoshihiro Ogawa; Tohru Funahashi; Iichiro Shimomura
Journal:  PLoS One       Date:  2013-10-01       Impact factor: 3.240

10.  SMRT repression of nuclear receptors controls the adipogenic set point and metabolic homeostasis.

Authors:  Russell R Nofsinger; Pingping Li; Suk-Hyun Hong; Johan W Jonker; Grant D Barish; Hao Ying; Sheue-Yann Cheng; Mathias Leblanc; Wei Xu; Liming Pei; Yeon-Joo Kang; Michael Nelson; Michael Downes; Ruth T Yu; Jerrold M Olefsky; Chih-Hao Lee; Ronald M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.